NEWS & MEDIA

BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia

Accelemd’s Cogentix Medical aquired by Laborie for $242M

Cogentix Medical Enters Definitive Merger Agreement to be Acquired by Laborie Medical Technologies for a Purchase Price of $3.85 Per Share in Cash

Sol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Sol-Gel raises $75M

Ladenburg Thalmann Financial Services initiated coverage on shares of Urogen Pharma

Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)

Arkin Bioventures’ Censa Pharmaceuticals raised $10M as part of a strategic long-term agreement with Retrophin

Merck, China’s WuXi AppTec and Mori Arkin to Launch Biotech Incubator in Israel

BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia

Urogen,Israeli urological cancer treatment developer raised 20% more than planned in Nasdaq IPO

Urogen Pharma rasise $58M in Nasdaq IPO

Arkin & Phoenix set up $60m biomed investment fund

Arkin Holdings and Primera Capital Lead an Investment of $13M in BioSight for an Innovative Treatment of Acute Leukemia

Israel’s Metabomed raises $18 mln for cancer-metabolism drugs

Mori Arkin personal history on Forbes 2015 billionaire rankings

Israeli shareholder Arkin rejects Mylan Perrigo bid

Moshe Arkin, Former Board Member at PERRIGO, bibliography

Israeli Perrigo shareholder slams Mylan’s $27 billion offer

Merck buys cCAM Biotherapeutics for up to $605m

cCAM Biotherapeutics receives FDA approval to initiate phase One trial for CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy

Mori Arkin in talks to buy Sol-Gel

Perrigo up for sale

Arkin Holdings lowers stake in Perrigo (PRGO) to 5.35%

Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service

Perrigo buys Israel’s Agis for $818m